The American Cancer Society's annual Cancer Statistics report has delivered historic news: overall cancer death rates in the United States have fallen 33% since 1991, and five-year survival rates for the 20 most common cancers have collectively reached their highest level ever recorded. The improvements are driven by three converging advances: immunotherapy, targeted molecular therapies, and dramatically improved early detection.
Immunotherapy has been the most transformative development. Checkpoint inhibitors β drugs that essentially release the immune system's brakes and allow it to attack cancer cells β have produced durable remissions in patients with melanoma, lung cancer, and bladder cancer who previously had very limited treatment options. Approximately 40% of melanoma patients treated with combination immunotherapy are alive ten years after diagnosis, compared to a median survival of 9 months with chemotherapy a decade ago.
CAR-T cell therapy, which engineers a patient's own immune cells to target their specific cancer, is producing complete remissions in certain blood cancers that were previously fatal. The FDA has now approved CAR-T therapies for six different cancer types, and over 40 new indications are in late-stage clinical trials.
Early detection technology has improved dramatically. Multi-cancer early detection blood tests (liquid biopsies) can now identify over 50 cancer types from a single blood draw, often years before symptoms develop. Grail's Galleri test is being integrated into annual physical exams at over 500 US health systems.
"We are witnessing the beginning of the end of cancer as a death sentence," said Dr. William Dahut, Chief Scientific Officer of the American Cancer Society.
